Biologics: How far can they go in Crohn's disease?

Katie A. Dunleavy, Darrell S. Pardi

Research output: Contribution to journalReview articlepeer-review


Crohn's disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn's disease and examines the positioning of medical therapy as emerging biologics break onto the market.

Original languageEnglish (US)
Article numbergoac049
JournalGastroenterology Report
StatePublished - 2022


  • Crohn's disease
  • JAK inhibitors
  • S1P-inhibitors
  • anti-TNFs
  • anti-integrins
  • anti-interleukins
  • biologics
  • medical treatment

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Biologics: How far can they go in Crohn's disease?'. Together they form a unique fingerprint.

Cite this